252 related articles for article (PubMed ID: 38252832)
1. Single-particle imaging of nanomedicine entering the brain.
Wei M; Qian N; Gao X; Lang X; Song D; Min W
Proc Natl Acad Sci U S A; 2024 Jan; 121(5):e2309811121. PubMed ID: 38252832
[TBL] [Abstract][Full Text] [Related]
2. Multimodal and multiscale optical imaging of nanomedicine delivery across the blood-brain barrier upon sonopermeation.
May JN; Golombek SK; Baues M; Dasgupta A; Drude N; Rix A; Rommel D; von Stillfried S; Appold L; Pola R; Pechar M; van Bloois L; Storm G; Kuehne AJC; Gremse F; Theek B; Kiessling F; Lammers T
Theranostics; 2020; 10(4):1948-1959. PubMed ID: 32042346
[No Abstract] [Full Text] [Related]
3. Multifunctional Nanocarriers for diagnostics, drug delivery and targeted treatment across blood-brain barrier: perspectives on tracking and neuroimaging.
Bhaskar S; Tian F; Stoeger T; Kreyling W; de la Fuente JM; Grazú V; Borm P; Estrada G; Ntziachristos V; Razansky D
Part Fibre Toxicol; 2010 Mar; 7():3. PubMed ID: 20199661
[TBL] [Abstract][Full Text] [Related]
4. Drug delivery across the blood-brain barrier: recent advances in the use of nanocarriers.
Mulvihill JJ; Cunnane EM; Ross AM; Duskey JT; Tosi G; Grabrucker AM
Nanomedicine (Lond); 2020 Jan; 15(2):205-214. PubMed ID: 31916480
[TBL] [Abstract][Full Text] [Related]
5.
Gallego L; Ceña V
Expert Opin Drug Deliv; 2020 Nov; 17(11):1541-1554. PubMed ID: 32791861
[TBL] [Abstract][Full Text] [Related]
6. Cellular and Molecular Targeted Drug Delivery in Central Nervous System Cancers: Advances in Targeting Strategies.
Zhao X; Ye Y; Ge S; Sun P; Yu P
Curr Top Med Chem; 2020; 20(30):2762-2776. PubMed ID: 32851962
[TBL] [Abstract][Full Text] [Related]
7. Quantitative Label-Free Chemical Imaging of PLGA Nanoparticles in Cells and Tissues with Single-Particle Sensitivity.
Gao X; Lang X; El Khoury E; Wei M; Qian N; Min W
Nano Lett; 2024 Jan; 24(3):1024-1033. PubMed ID: 38207237
[TBL] [Abstract][Full Text] [Related]
8. Nanomedicine as a non-invasive strategy for drug delivery across the blood brain barrier.
Tam VH; Sosa C; Liu R; Yao N; Priestley RD
Int J Pharm; 2016 Dec; 515(1-2):331-342. PubMed ID: 27769885
[TBL] [Abstract][Full Text] [Related]
9. Peptide-decorated nanocarriers penetrating the blood-brain barrier for imaging and therapy of brain diseases.
Gao X; Xu J; Yao T; Liu X; Zhang H; Zhan C
Adv Drug Deliv Rev; 2022 Aug; 187():114362. PubMed ID: 35654215
[TBL] [Abstract][Full Text] [Related]
10. Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders.
Neganova ME; Aleksandrova YR; Sukocheva OA; Klochkov SG
Semin Cancer Biol; 2022 Nov; 86(Pt 2):805-833. PubMed ID: 35779712
[TBL] [Abstract][Full Text] [Related]
11. Comparative study of preclinical mouse models of high-grade glioma for nanomedicine research: the importance of reproducing blood-brain barrier heterogeneity.
Brighi C; Reid L; Genovesi LA; Kojic M; Millar A; Bruce Z; White AL; Day BW; Rose S; Whittaker AK; Puttick S
Theranostics; 2020; 10(14):6361-6371. PubMed ID: 32483457
[TBL] [Abstract][Full Text] [Related]
12. Strategic nanocarriers to control neurodegenerative disorders: Concept, challenges, and future perspective.
Ashique S; Afzal O; Yasmin S; Hussain A; Altamimi MA; Webster TJ; Altamimi ASA
Int J Pharm; 2023 Feb; 633():122614. PubMed ID: 36646255
[TBL] [Abstract][Full Text] [Related]
13. Carbon Dots: A Future Blood-Brain Barrier Penetrating Nanomedicine and Drug Nanocarrier.
Zhang W; Sigdel G; Mintz KJ; Seven ES; Zhou Y; Wang C; Leblanc RM
Int J Nanomedicine; 2021; 16():5003-5016. PubMed ID: 34326638
[TBL] [Abstract][Full Text] [Related]
14. Nanomedicine based strategies for oligonucleotide traversion across the blood-brain barrier.
Amulya E; Sikder A; Vambhurkar G; Shah S; Khatri DK; Raghuvanshi RS; Singh SB; Srivastava S
J Control Release; 2023 Feb; 354():554-571. PubMed ID: 36649742
[TBL] [Abstract][Full Text] [Related]
15. Nanocarriers for Effective Brain Drug Delivery.
Comoglu T; Arisoy S; Akkus ZB
Curr Top Med Chem; 2017; 17(13):1490-1506. PubMed ID: 28017157
[TBL] [Abstract][Full Text] [Related]
16. In Vitro Blood-Brain Barrier Models for Nanomedicine: Particle-Specific Effects and Methodological Drawbacks.
Sitia L; Catelani T; Guarnieri D; Pompa PP
ACS Appl Bio Mater; 2019 Aug; 2(8):3279-3289. PubMed ID: 35030770
[TBL] [Abstract][Full Text] [Related]
17. Targeted transport of nanocarriers into brain for theranosis with rabies virus glycoprotein-derived peptide.
Fu C; Xiang Y; Li X; Fu A
Mater Sci Eng C Mater Biol Appl; 2018 Jun; 87():155-166. PubMed ID: 29549945
[TBL] [Abstract][Full Text] [Related]
18. Targeting central nervous system pathologies with nanomedicines.
Mizrahy S; Gutkin A; Decuzzi P; Peer D
J Drug Target; 2019; 27(5-6):542-554. PubMed ID: 30296187
[TBL] [Abstract][Full Text] [Related]
19. Insights into Targeted and Stimulus-Responsive Nanocarriers for Brain Cancer Treatment.
Abousalman-Rezvani Z; Refaat A; Dehghankelishadi P; Roghani-Mamaqani H; Esser L; Voelcker NH
Adv Healthc Mater; 2024 May; 13(12):e2302902. PubMed ID: 38199238
[TBL] [Abstract][Full Text] [Related]
20. Development of Novel Therapeutics Targeting the Blood-Brain Barrier: From Barrier to Carrier.
Li J; Zheng M; Shimoni O; Banks WA; Bush AI; Gamble JR; Shi B
Adv Sci (Weinh); 2021 Aug; 8(16):e2101090. PubMed ID: 34085418
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
